Capecitabine Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 500 mg tablets 150 mg tablets
Reference Brands: Xeloda®(EU & US)
Category:
Oncology Cancer Care
Capecitabine is an oral chemotherapy used for breast, colorectal, and gastric cancer. Available in 500 mg and 150 mg tablets under the brand Xeloda® in the US and EU.
Capecitabine is available in Tablets
and strengths such as 500 mg tablets 150 mg tablets.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Capecitabine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Capecitabine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Capecitabine, marketed as Xeloda®, is an oral chemotherapy agent used in the treatment of breast cancer, colorectal cancer, and gastric cancer. As a prodrug of 5-fluorouracil (5-FU), Capecitabine is administered in 500 mg and 150 mg tablet strengths in both the US and EU markets. Its oral formulation makes it convenient for outpatient therapy and home administration. Manufactured under stringent GMP guidelines, Capecitabine is a crucial product for B2B oncology pharmaceutical companies targeting cancer care centers and oncology specialists. It presents significant opportunities for global distribution and licensing.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing